Overcoming asset transfer challenges during a merger and acquisition (M&A)

In this video, Parexel’s Paul Bridges speaks with Phil Smith about how pharma and biotech can overcome common operational challenges and key considerations for a more successful asset transfer.

Return to Insights Center

Related Insights

Webinar

Assessing appropriate use of ECAs in clinical trials

May 28, 2023

Playbook

Early-phase development strategies for navigating regulatory complexity in the EU

Apr 29, 2024

Article

How a joined-up development strategy pays off for early-stage biotechs

May 19, 2021

Blog

Studying multiple versions of a cellular or gene therapy product in an early-phase clinical trial

Nov 19, 2021

Article

Near-term strategies for biotech drug developers facing shifting healthcare dynamics

Feb 14, 2024

Article

Expedited Pathways Comparisons - US EU CHN

Oct 19, 2021

Playbook

What emerging trends in the FDA’s most coveted designations might tell us

Feb 8, 2024

Article

8 things you need to know about eCTDs in China

Jul 1, 2022

Webinar

Challenges and best practices for developing Antibody-Drug Conjugates (ADCs)

Nov 12, 2024

Blog

Preparing for the New Era of Hybrid Regulatory Inspections

Jul 11, 2022

Article

How biotechs can strengthen their value story with advanced analytics

Feb 15, 2022

Article

Getting to ‘No’ fast is more important when you are small

Mar 4, 2022

Related Insights

Webinar

Assessing appropriate use of ECAs in clinical trials

May 28, 2023

Playbook

Early-phase development strategies for navigating regulatory complexity in the EU

Apr 29, 2024

Article

How a joined-up development strategy pays off for early-stage biotechs

May 19, 2021

Blog

Studying multiple versions of a cellular or gene therapy product in an early-phase clinical trial

Nov 19, 2021

Article

Near-term strategies for biotech drug developers facing shifting healthcare dynamics

Feb 14, 2024

Article

Expedited Pathways Comparisons - US EU CHN

Oct 19, 2021

Show more